Evaxion Biotech
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 2008-01-01
- Employees
- 49
- Market Cap
- -
- Introduction
Evaxion Biotech A/S engages in the discovery and development of immunotherapies for cancer and infectious diseases. Its technologies include the immuno-oncology platform PIONEER, the bacterial disease platform EDEN, the viral disease platform RAVEN, and the proprietary AI platform technology ObsERV. The company was founded by Niels Iversen M?ller and Andreas Holm Mattsson on August 11, 2008 and is headquartered in Hoersholm, Denmark.
Evaxion Biotech Announces Change in ADS Ratio to Enhance Liquidity
Evaxion Biotech announced a one-for-five reverse ADS split effective January 13, 2025, aiming to enhance liquidity and potentially increase ADS trading price. The company, leveraging AI for vaccine and immunotherapy development, focuses on cancer, bacterial diseases, and viral infections.
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
Evaxion Biotech's AI-Immunology™ platform validated in three clinical trials, showing strong correlation between AI-predicted vaccine targets and immunological responses, with top-ranked targets generating the strongest outcomes, highlighting the platform's potential in vaccine design.
Recent clinical data confirms significantly improved predictive power of Evaxion's AI
Evaxion Biotech's AI-Immunology™ platform predicts 79% of vaccine targets triggering a tumor-specific immune response in phase 2 trial, up from 58% in phase 1, due to iterative learning and advanced bioinformatics.
Evaxion reports convincing one-year data from phase 2 trial on AI-designed personalized
Evaxion Biotech reports 69% Overall Response Rate in Phase 2 trial of EVX-01, with 15/16 patients showing tumor reduction. 79% of vaccine targets triggered immune response, and a positive correlation was observed between AI-Immunology™ predictions and neoantigen immune response (p=0.00013). EVX-01 holds significant commercial potential for melanoma treatment.
Evaxion reports promising phase 2 trial results for cancer vaccine
Evaxion Biotech's phase 2 trial of EVX-01, a personalized cancer vaccine, showed a 69% Overall Response Rate in advanced melanoma patients. The AI-Immunology™ platform-designed vaccine targets neoantigens, triggering a targeted immune response in 79% of cases. With melanoma cases projected to reach 510,000 by 2040, EVX-01's potential market value is significant. Final trial results are expected in Q3 2025.
Evaxion reports 69% Overall Response Rate in its phase 2 trial on lead cancer vaccine
11/16 patients in Evaxion's phase 2 trial showed 69% Overall Response Rate with tumor reduction in 15/16 patients. Full data to be presented at ESMO 2024 and discussed in a webinar with Professor Georgina V. Long on September 18, 2024.
© Copyright 2025. All Rights Reserved by MedPath